Poland's pharmaceuticals market set for CAGR of 7% through 2014

Poland is an important pharmaceutical market in Central and Eastern Europe (CEE), and is a relatively well-developed market compared with those to the east, according to Business Monitor International. Poland’s total drug expenditure and projected growth rates are below Russia and Turkeys respective figures.

However, Poland’s considerably more favorable business environment makes it a more attractive investment opportunity, which is illustrated in BMI’s latest Pharmaceuticals and Healthcare Business Environment Ratings (BERs) index. Poland remains in second place in CEE for the first quarter of 2011, with an overall score of 62.5. A strong performance in 2009 and significant growth projected for 2010 & 2011 benefit the high Industry Rewards score. The BER score has edged above the Q410 figure as a result of an improved Country Risk outlook.

BMI forecasts that Poland’s pharmaceutical market will increase from 30.25 billion zlotys ($10.56 billion) in 2009 to 32.23 billion zlotys ($11.13 billion) in 2010. Between 2009 and 2014, BMI projects a compound annual growth rate (CAGR) of 7.04% in local currency terms and 8.80% in US dollars.